Conference Home

Scientific Agenda

Accommodations & Travel

Sponsorship


OncologyEducation.com’s Best of ASCO® Conference is a program licensed by the American Society of Clinical Oncology and will be held on July 20, 2018 in Vancouver, BC. The focus of this event will be to provide medical oncologists and other healthcare practitioners with a summary of the most significant treatment advances presented at the ASCO 2018 Annual Meeting, with presentations focused on several key disease sites.
 

Meeting Objectives 

1. To summarize the most significant treatment advances presented at ASCO 2018

2. To review the current standard of care for key malignancies

3. To discuss the current controversies in the management of speci­fic cancers
 

Target Audience

Medical oncologists, pharmacists, nurses, and other oncology healthcare professionals.


FEES

 

REGULAR

Physicians

$195

Nurses/Pharmacists/Allied Healthcare Providers

$105

Residents/Students

Complimentary



Other Information

*This meeting has been approved by the American Society of Clinical Oncology. ASCO is not the CME provider for this activity.

**Best of ASCO® and any related logos are trademarks of the American Society of Clinical Oncology®.


Contact Information

For more information, please send requests to  andrea@oncologyeducation.com.


ABOUT THE CHAIRS

Dr. Sharlene Gill, BSc (Pharm), MD, MPH, FACP, FRCPC, is a medical oncologist at the BC Cancer Agency - Vancouver specializing in gastrointestinal (GI) malignancies, and a Professor of Medicine at the University of British Columbia. She received a Bachelor's of Science in Pharmacy and an MD (Doctor of Medicine) from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic and a Master's of Public Health from the Harvard School of Public Health. Her areas of expertise are colorectal, pancreatic and hepatobiliary cancers. In addition to her clinical work, she is actively engaged in education and research, with over 80 peer-reviewed publications and book chapters to her credit. She is currently an MBA Candidate at Kenan-Flagler Business School (University of North Carolina, Class of 2017).

 

 

Dr. Daniel Heng, MD, FRCPC, is a Staff Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta and a Clinical Associate Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and trained at the BC Cancer Agency and Cleveland Clinic Taussig Cancer Institute. He has a Masters of Public Health from Harvard University and has a keen interest in outcomes, prognostic factors and clinical trials research in metastatic renal cell carcinoma and other genitourinary malignancies. He is the Chair of the International mRCC Database Consortium which includes over 28 cancer centers worldwide.

 

 


Oncology Clinical News

Powered by OBR Oncology